C14018 Alisertib vs Placebo in Combo w/ Paclitaxel for SCLC

This study is designed to evaluate the efficacy and safety of alisertib in combination with paclitaxel compared with placebo + paclitaxel in patients with Small Cell Lung Cancer who have relapsed or did not respond to first line standard therapy.

September 25, 2015